Phosplatin Therapeutics Inc. — Form D
Phosplatin Therapeutics Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2018-11-08. The offering totals $16.6M, of which $16.6M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-11-08
- Form: D
- Accession: 0001757705-18-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $16.6M
- Amount sold: $16.6M
- Investors: 48
- Date of first sale: 2018-10-31
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-325409
Issuer
- Name: Phosplatin Therapeutics Inc.
- CIK: 0001757705
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 1350 AVENUE OF THE AMERICAS, NEW YORK, NY, 10019
- Phone: 646-380-2441
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Peter Espig | Director | VANCOUVER, A1 |
| Matthew Price | Director | Brownsburg, IN |
| Matthew Price | Executive Officer | Brownsburg, IN |
| John Porter | Director | Woods Cross, UT |
| Rosita Leong | Director | New York, NY |
| Robert Fallon | Director | New York, NY |
| Robert Fallon | Executive Officer | New York, NY |
| John Caouette | Director | New York, NY |
| Frances Bonham | Executive Officer | New York, NY |
| Neil Sunderland | Director | New York, NY |
| Charles Stuckey | Director | New York, NY |
| Elizabeth Tallett | Director | New York, NY |
| Fallon Robert | Director | New York, NY |
| Fallon Robert | Executive Officer | New York, NY |
Other filings by this issuer (2)
More